Ann: Trading Halt, page-91

Itsa, yes kudos to you, Sammy, Imp, Mac, Learner and the long termers who have been here from the day of MS and Acro trials.

Those frustrating 'false starts' and data generated...is now unlocking latent shareholder value with DMD.

Not many Phase 2B 'pivotal' trials going on where efficacy end points were already proven in P2.

We are one 12 month trial away from market approval - just have to replicate P2 results.

Still lots of risk - but we know the 25Mg dosing arm will work!


That will be the supporting pillar for approval - while we find the 'goldilocks' higher dose.

"Steady pace" for share price appreciation?

Not sure - there will be a 'gap up' and some....to reflect the de-risking occurring now.

I'm looking at the +$1.70 un-risked valuation in the analyst reports as the beacon once funding is announced.

We'll get there in the new year imo.
.